8-K 1 b40725mce8-k.txt THE MEDICINES COMPANY 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2001 The Medicines Company (Exact Name of Registrant as Specified in Charter) Delaware 000-31191 04-3324394 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) One Cambridge Center Cambridge, MA 02142 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (617) 225-9099 Not Applicable (Former Name or Former Address, if Changed Since Last Report) 2 ITEM 5. OTHER EVENTS. On October 3, 2001, The Medicines Company issued an announcement in connection with its revised revenue guidance for 2001 and 2002. The full text of the press release issued in connection with the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits.
Exhibit No. Description ----------- ----------- 99.1 Press release dated October 3, 2001 announcing revised revenue guidance by the Registrant for 2001 and 2002
-2- 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 4, 2001 THE MEDICINES COMPANY By: /s/ Peyton J. Marshall ----------------------------------- Name: Peyton J. Marshall Title: Senior Vice President and Chief Financial Officer -3- 4 EXHIBIT INDEX
Exhibit No. Description ----------- ----------- 99.1 Press release dated October 3, 2001 announcing revised revenue guidance by the Registrant for 2001 and 2002